Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
ad, added, adjuvant, aforementioned, alphavax, antibody, antiviral, appeal, aspect, Astra, attenuated, attrition, backbone, Bavarian, Bayer, billion, Biogen, biosimilar, biotech, bitten, boost, BPCIA, Brazil, burn, canary, carryforward, cellular, cochlear, complicated, complimentary, conclusion, copy, deployment, difficulty, disorder, dominated, encompassed, endeavor, explosive, fatal, Florida, fluctuating, fluctuation, frequently, Genocea, Genzyme, Glaxo, grace, grave, GSK, halted, Hawaii, headache, hemorrhagic, Henry, HJF, hoc, inconvenience, Indian, inInternal, institutionalized, insulate, interchangeable, introduction, Jackson, killed, linked, live, mailed, medial, Merial, molecule, mosquito, mutually, NanoBio, NE, Nordic, notification, notified, opportunity, outbreak, pain, parasite, partner, Pasteur, pediatric, pipeline, placebo, pox, PPACA, prematurely, pronouncement, prudent, Quark, quick, rash, ratably, rational, reevaluated, regimen, replicate, resistance, resolved, Room, Rotterdam, Sanaria, sanofi, screen, Setpember, shedding, sheep, Similarly, SmithKline, Sound, split, statistical, Sterile, Street, strongly, substantive, subunit, swine, synthetic, tailor, tetravalent, Thailand, transmission, tropical, undelivered, underscore, unilaterally, unpredictable, urban, VaxGen, Venezuela, vii, viii, Zeneca
Removed:
abetting, adenoviral, afford, agent, aid, aiding, Angiotech, anniversary, apparent, Applera, avoidance, awarded, Biomanufacturing, BioSepra, bond, breast, build, cancellation, carrier, casualty, Chairman, chemoradiation, Cobra, cohort, collect, colon, colostomy, combined, considerable, conspiracy, constitute, consultation, conventional, Cowen, crucial, curb, currency, damage, death, decade, demonstration, designation, diagnosed, die, dose, EITF, emerging, encounter, enrolled, enrolling, Erbitux, evaluable, eventual, excellent, feasible, frail, futility, gaining, governing, headquartered, identifiable, impermissible, improvement, individually, induced, ineffective, injection, Kingdom, led, liable, literature, LLC, lung, manage, measuring, melanoma, merge, merit, misuse, monitored, MPH, North, observed, onset, optimizing, Oxford, Pall, pathological, penalty, planned, Plasmodium, Plc, point, preempted, prescribed, privacy, proceed, prolong, prolonged, promulgated, prosecuted, pursued, Radiology, randomized, ratio, releasing, reliance, repayment, replacing, reputation, resale, resection, risen, sarcoma, scheduling, secrete, selectively, settlement, SG, sinking, Society, solid, sparing, sphincter, strong, suggest, surgery, surgical, survival, swap, Task, termed, Thornton, thrombotic, Tracking, underwent, Univax, unlawful, unsuitable, urgently, validation, volume, VWAP, WinRho, yielded, ZioPharm
Filing tables
Filing exhibits
Related press release
GNVC similar filings
Filing view
External links
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders:
GenVec, Inc.:
We consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-164862, No. 333-133366, No. 333-123968, No. 333-101963 and No. 333-76886), on Form S-4 (No. 333-105320) and on Form S-8 (File No. 333-110446, No. 333-55590, No. 333-55586 and No. 333-55584) of GenVec, Inc. of our reports dated March 11, 2011, with respect to (1) the balance sheets of GenVec, Inc., as of December 31, 2010 and 2009 and the related statements of operations, stockholders’ equity and comprehensive income (loss) and cash flows for each of the years in the three-year period ended December 31, 2010, and (2) the effectiveness of internal control over financial reporting as of December 31, 2010, which reports appear in the December 31, 2010 Annual Report on Form 10-K of GenVec, Inc.
/s/KPMG LLP
McLean, Virginia
March 11, 2011